These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15055993)

  • 1. Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.
    Moriyama H; Tsukida T; Inoue Y; Yokota K; Yoshino K; Kondo H; Miura N; Nishimura S
    J Med Chem; 2004 Apr; 47(8):1930-8. PubMed ID: 15055993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure--activity relationships of azasugar-based MMP/ADAM inhibitors.
    Moriyama H; Tsukida T; Inoue Y; Kondo H; Yoshino K; Nishimura S
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2737-40. PubMed ID: 12873504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors.
    Moriyama H; Tsukida T; Inoue Y; Kondo H; Yoshino K; Nishimura S
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2741-4. PubMed ID: 12873505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New type of metalloproteinase inhibitor: design and synthesis of new phosphonamide-based hydroxamic acids.
    Sawa M; Kiyoi T; Kurokawa K; Kumihara H; Yamamoto M; Miyasaka T; Ito Y; Hirayama R; Inoue T; Kirii Y; Nishiwaki E; Ohmoto H; Maeda Y; Ishibushi E; Inoue Y; Yoshino K; Kondo H
    J Med Chem; 2002 Feb; 45(4):919-29. PubMed ID: 11831904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New strategy for antedrug application: development of metalloproteinase inhibitors as antipsoriatic drugs.
    Sawa M; Tsukamoto T; Kiyoi T; Kurokawa K; Nakajima F; Nakada Y; Yokota K; Inoue Y; Kondo H; Yoshino K
    J Med Chem; 2002 Feb; 45(4):930-6. PubMed ID: 11831905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-hydroxamate 5-phenylpyrimidine-2,4,6-trione derivatives as selective inhibitors of tumor necrosis factor-alpha converting enzyme.
    Duan JJ; Lu Z; Wasserman ZR; Liu RQ; Covington MB; Decicco CP
    Bioorg Med Chem Lett; 2005 Jun; 15(12):2970-3. PubMed ID: 15908214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and activity of quinolinylmethyl P1' alpha-sulfone piperidine hydroxamate inhibitors of TACE.
    Zhang C; Lovering F; Behnke M; Zask A; Sandanayaka V; Sun L; Zhu Y; Xu W; Zhang Y; Levin JI
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3445-8. PubMed ID: 19464885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological activity of selective azasugar-based TACE inhibitors.
    Tsukida T; Moriyama H; Inoue Y; Kondo H; Yoshino K; Nishimura S
    Bioorg Med Chem Lett; 2004 Mar; 14(6):1569-72. PubMed ID: 15006405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.
    Venkatesan AM; Davis JM; Grosu GT; Baker J; Zask A; Levin JI; Ellingboe J; Skotnicki JS; Dijoseph JF; Sung A; Jin G; Xu W; McCarthy DJ; Barone D
    J Med Chem; 2004 Dec; 47(25):6255-69. PubMed ID: 15566296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones.
    Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Rao BG
    Bioorg Med Chem Lett; 2008 Jan; 18(1):44-8. PubMed ID: 18054488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design strategies for the identification of MMP-13 and Tace inhibitors.
    Skotnicki JS; DiGrandi MJ; Levin JI
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
    Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
    J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structure-activity relationships of 5,6,7,8-tetrahydropyrido[3,4-b]pyrazine-based hydroxamic acids as HB-EGF shedding inhibitors.
    Yoshiizumi K; Yamamoto M; Miyasaka T; Ito Y; Kumihara H; Sawa M; Kiyoi T; Yamamoto T; Nakajima F; Hirayama R; Kondo H; Ishibushi E; Ohmoto H; Inoue Y; Yoshino K
    Bioorg Med Chem; 2003 Feb; 11(3):433-50. PubMed ID: 12517439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE.
    Levin JI
    Curr Top Med Chem; 2004; 4(12):1289-310. PubMed ID: 15320727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
    Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
    J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
    Kottirsch G; Koch G; Feifel R; Neumann U
    J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
    Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Davis JM; Grosu GT; Baker J; Ellingboe J; Zask A; Levin JI; Sandanayaka VP; Du M; Skotnicki JS; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R; Tillett J; Zhao W; McDevitt J; Xu ZB
    J Med Chem; 2003 Jun; 46(12):2376-96. PubMed ID: 12773042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of macrocyclic hydroxamic acids containing biphenylmethyl derivatives at P1', a series of selective TNF-alpha converting enzyme inhibitors with potent cellular activity in the inhibition of TNF-alpha release.
    Xue CB; He X; Corbett RL; Roderick J; Wasserman ZR; Liu RQ; Jaffee BD; Covington MB; Qian M; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
    J Med Chem; 2001 Oct; 44(21):3351-4. PubMed ID: 11585440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.